In Brief: Vagistat-1
This article was originally published in The Tan Sheet
Executive Summary
Vagistat-1: Advertising for Bristol-Myers Squibb's one-day vaginal yeast infection treatment is being handled by Wells Rich Greene BDDP (New York City). The tioconazole 6.5% OTC treatment, approved by FDA Feb. 11, is being shipped on a limited basis, the company says. A professional "coming soon" ad for Vagistat-1 appearing in the April 17 edition of the New England Journal of Medicine highlights the treatment's "one dose...broad-spectrum activity" and notes that Vagistat-1 will be "available this spring"...